| # | Title | Journal | Year | Citations |
|---|
| 1 | Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition | Lancet, The | 2016 | 586 |
| 2 | Reducing antimicrobial use in food animals | Science | 2017 | 448 |
| 3 | Antibiotic Resistance in India: Drivers and Opportunities for Action | PLoS Medicine | 2016 | 350 |
| 4 | Trends in Antibiotic Resistance in Coagulase-Negative Staphylococci in the United States, 1999 to 2012 | Antimicrobial Agents and Chemotherapy | 2014 | 106 |
| 5 | Childhood vaccines and antibiotic use in low- and middle-income countries | Nature | 2020 | 85 |
| 6 | The path of least resistance: aggressive or moderate treatment? | Proceedings of the Royal Society B: Biological Sciences | 2014 | 79 |
| 7 | UN High-Level Meeting on antimicrobials—what do we need? | Lancet, The | 2016 | 69 |
| 8 | Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016 | Antibiotics | 2017 | 42 |
| 9 | Multidrug- and Carbapenem-ResistantPseudomonas aeruginosain Children, United States, 1999–2012 | Journal of the Pediatric Infectious Diseases Society | 2016 | 41 |
| 10 | Costs of surgical procedures in Indian hospitals | BMJ Open | 2013 | 39 |
| 11 | Antimicrobial resistance in paediatric Streptococcus pneumoniae isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis | Lancet Microbe, The | 2021 | 36 |
| 12 | Economics of Antibiotic Growth Promoters in Livestock | Annual Review of Resource Economics | 2015 | 31 |
| 13 | Funders: The missing link in equitable global health research? | PLOS Global Public Health | 2022 | 31 |
| 14 | Increasing Resistance of Acinetobacter Species to Imipenem in United States Hospitals, 1999–2006 | Infection Control and Hospital Epidemiology | 2010 | 28 |
| 15 | All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study | Lancet Infectious Diseases, The | 2022 | 28 |
| 16 | Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: Evidence from the Global Enteric Multicenter Study | PLoS Neglected Tropical Diseases | 2020 | 25 |
| 17 | Valuing vaccines using value of statistical life measures | Vaccine | 2014 | 24 |
| 18 | Incentivizing hospital infection control | Proceedings of the National Academy of Sciences of the United States of America | 2019 | 22 |
| 19 | Antibacterial R&D incentives | Nature Reviews Drug Discovery | 2011 | 18 |
| 20 | Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus | Proceedings of the National Academy of Sciences of the United States of America | 2022 | 18 |
| 21 | India’s Battle against COVID-19: Progress and Challenges | American Journal of Tropical Medicine and Hygiene | 2020 | 14 |
| 22 | Diversify or focus? Spending to combat infectious diseases when budgets are tight | Journal of Health Economics | 2012 | 13 |
| 23 | Quantifying uncertainty about future antimicrobial resistance: Comparing structured expert judgment and statistical forecasting methods | PLoS ONE | 2019 | 13 |
| 24 | Public health facility quality and child immunization outcomes in rural India: A decomposition analysis | Vaccine | 2022 | 7 |
| 25 | Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions | ACS Infectious Diseases | 2019 | 6 |
| 26 | Relationship between early‐life nutrition and ages at menarche and first pregnancy, and childbirth rates of young adults: Evidence from APCAPS in India | Maternal and Child Nutrition | 2020 | 5 |
| 27 | Reply to Abat et al.: Improved policies necessary to ensure an effective future for antibiotics | Proceedings of the National Academy of Sciences of the United States of America | 2018 | 4 |
| 28 | Malaria Vaccine Impact on Drug-Susceptible and Resistant Cases and Deaths: A Modeling Study | SSRN Electronic Journal | 0 | 1 |
| 29 | Reply to Arnold and Beavin | Clinical Infectious Diseases | 2018 | 0 |
